語言

Congratulations to Dr. Ruby Chen’s team for winning the 2022 IBMI Award

The Awards ceremony was held on 3rd December 2022 in Taipei Nangang Exhibition Center. Dr. Ruby Chen’s team getting the award for their study of a novel therapeutic and diagnostic antibody to combat ALS and related neurodegenerative diseases.

TDP-43 proteinopathies are present in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD). Especially, TDP-43 aggregates are associated with >95% of ALS cases. Currently, there is no cure or treatment for these diseases. The study has demonstrated that misfolded TDP-43 oligomers are neurotoxic and identified them in the brain and spinal cord of ALS patients. They further produced the mouse anti-TDP-43 oligomer-specific monoclonal antibodies (TDP-O antibodies) and validated that one TDP-O antibody, TDP-O9, has therapeutic efficacy in TDP-43 oligomer-injected wild-type mice and TDP-43 transgenic mice. The i.v. injection of the antibody significantly improved motor behavior and reserved motor neurons in the spinal cord. Now, the team is developing the humanized TDP-43 oligomer-specific monoclonal antibody.

Bravo!

 2022IBMIAward
Current Research Team (right to left): Dr. Yun-Ru Chen, Dr. Wei-Wei Chang Research assistant, Ms. Shih-Han Huang, PhD candidate Mr. Yuh Shen Lye, and PhD candidate Mr.Jeng-Jung Wu.

LATEST NEWS

  • 2023 Genomic Epidemiology Workshop +

    Read More
  • Learning from nature: StnK3 is the epimerase controlling β-methyl amino acid stereochemistry +

    Read More
  • The critical point to treatment from the inside out: hybrid inorganic/organic nanoparticles with exosomes for cancer treatment +

    Read More
  • Clarification Statement +

    Read More
  • Excess sugar intake increases the risk of pancreatic tumorigenesis +

    Read More
  • 1
  • 2
  • 3
  • 4